This bill aims to prohibit the use of step therapy protocols for the treatment of neurological conditions in Minnesota. It introduces new legal language under Minnesota Statutes, chapter 62Q, specifically section 62Q.1842. The bill defines key terms such as "neurological condition," which refers to disorders causing impairment in neurological function, and "step therapy protocol," which is a method requiring patients to try less expensive treatments before more expensive ones.

Under the new provisions, health plans that cover treatments for neurological conditions cannot limit or exclude coverage for FDA-approved drugs included in their formulary by requiring patients to follow a step therapy protocol if the drug's use aligns with FDA-approved indications and clinical practice guidelines. The bill is set to take effect on January 1, 2027, applying to health plans offered, issued, or renewed on or after that date.